Amgen's SWOT analysis: stock outlook amid obesity drug race, pipeline progress
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
FiercePharma8h
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
PMLiVE10h
Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication
Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...
Here's Why Amgen (AMGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Pharma Letter1d
EC approval allows earlier access to Blincyto
The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...
pharmaphorum1d
Amgen pays $2.7bn to harness BeiGene’s China marketing muscle
The Chinese company also gets commercialisation rights to three already-marketed cancer drugs, as well as co-development rights to 20 candidates in its oncology pipeline, while Amgen gets to ...
Outsourcing-pharma8d
The largest pharma acquisitions of 2024
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is pleased to ...